Spyre logo: “Spyre” in navy capitalized text and “Therapeutics” in smaller navy capitalized text, deep pink “Y” antibody shape at the left

We are advancing a broad pipeline of potentially best-in-class antibodies. Learn more about the programs we are developing below.

STRATEGY
TARGET
PROGRAM
DISCOVERY
IND-ENABLING
CLINICAL

Potential best-in-class mAbsExtended half-life

α4β7
SPY001
IND-ENABLING

Our most advanced product candidate, SPY001, is designed to be a highly potent, selective, and fully humanized monoclonal immunoglobulin G1 antibody that binds selectively to the α4β7 integrin.

TL1A
SPY002
IND-ENABLING

Our co-lead product candidate, SPY002 is designed to be a highly potent, highly selective and fully humanized monoclonal antibody that binds to tumor necrosis factor-like ligand 1A ("TL1A").

IL-23
SPY003
Discovery
Novel MOA
SPY004
Discovery

Rational combinations

α4β7 + TL1A
SPY120
IND-ENABLING
α4β7 + IL-23
SPY130
Discovery
TL1A + IL-23
SPY230
Discovery
OUR PUBLICATIONSOTHER REFERENCES